Decision Aid for Women Newly Diagnosed With Breast Cancer

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorXiamen University

About this trial

The goal of this multi-center randomized controlled trial is to determine if the clinical decision aid (BCT Aid) works to help breast cancer patients participate in decision-making and make high-quality decisions, thereby improving the rate of breast-conserving surgery and quality of life. The main questions it aims to answer are:

Does the BCT Aid significantly increase the rate of breast-conserving surgery compared to usual care? Does the BCT Aid reduce decision conflict and decision regret, while improving shared decision-making and quality of life? Does the BCT Aid demonstrate better cost-effectiveness in terms of health resource utilization? Researchers will compare the BCT Aid to usual care (standard clinical consultation) to evaluate the effectiveness and cost-effectiveness of BCT Aid.

Participants will:

Be randomly assigned to either the intervention group (receiving the BCT Aid intervention for 6 months) or the control group (usual care).

Complete assessments including decision conflict and shared decision-making at baseline (T0), post-consultation with the surgeon (T1), 6 months (T2, post-intervention), and 12 months (T3, 6 months post-intervention), decision regret at T2 and T3, and quality of life at T0, T2, and T3, with additional EQ-5D-5L measurements at baseline, 3, 6, 9, and 12 months for cost-effectiveness analysis.

Have clinical outcomes (breast-conserving surgery rate) and health resource utilization data collected from medical records.

Eligibility criteria

Qualifiers

Age ≥ 18 years.

Newly diagnosed with breast cancer, with clinical stage 0-II, or stage III eligible for breast-conserving surgery after neoadjuvant chemotherapy.

Clinically eligible for breast-conserving surgery and considering one of the following surgical options: breast-conserving surgery, mastectomy, or mastectomy with reconstruction.

Clinically eligible for adjuvant therapy after surgery.

Disqualifiers

Male breast cancer patients.

Clinically eligible for only one surgical option or not candidates for surgery.

Have a history of other malignancies, except adequately treated cervical carcinoma in situ and basal cell carcinoma of the skin.

Presence of psychiatric disorders, visual or hearing impairments, or cognitive impairment.

Trial design

Treatments tested in this trial

  • BCT Aid
  • Usual Care

Treatment groups

160 Participants
are divided into 2 treatment groups

Sponsors and collaborators